Literature DB >> 29465435

Clinical manifestations of sickle cell disease in India: misconceptions and reality.

Dipty Jain1, Dipika Mohanty2.   

Abstract

PURPOSE OF REVIEW: In the past, milder clinical manifestations of sickle cell disease (SCD) have been described from India. However, recent data from some parts of India suggest that the severity of the disease can be compared to that of African phenotypes. This review therefore describes the varied clinical manifestation of SCD, the success of newborn screening programme, prenatal diagnosis and low dose hydroxyurea therapy in India. RECENT
FINDINGS: The varied clinical manifestations such as anemia, vaso-occlusive crisis, acute chest syndrome, renal involvement, stroke and so on vary from one part of the country to the other and also among different communities of India. Strategies for improving quality of life and controlling of SCD have been suggested. Certain factors other than genetics also play an important role in clinical manifestation of the disorder.
SUMMARY: The clinical diversity of SCD is described. The natural history of SCD in India is unfolding from newborn screening programme. The use of low-dose hydroxy urea therapy both in adults and children has brought down the incidences of crisis and provides great relief to the patients. The tailor-made programme for India as regards the control and management has been discussed.

Entities:  

Mesh:

Year:  2018        PMID: 29465435     DOI: 10.1097/MOH.0000000000000422

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  3 in total

1.  Endothelial dysfunction biomarkers in sickle cell disease: is there a role for ADMA and PAI-1?

Authors:  Suellen Rodrigues Martins; Sílvia Letícia de Oliveira Toledo; Aislander Junio da Silva; Fernanda Santos Mendes; Marina Mendes de Oliveira; Leticia Gonçalves Resende Ferreira; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Danyelle Romana Alves Rios; Patrícia Nessralla Alpoim; Melina de Barros Pinheiro
Journal:  Ann Hematol       Date:  2021-10-19       Impact factor: 3.673

Review 2.  Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.

Authors:  Thamal Darshana; David Rees; Anuja Premawardhena
Journal:  Orphanet J Rare Dis       Date:  2021-03-23       Impact factor: 4.123

3.  Sickle cell disease: More than a century of progress. Where do we stand now?

Authors:  Valentine Brousse; David C Rees
Journal:  Indian J Med Res       Date:  2021-07       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.